Volume 26, Issue 5 (Iranian South Medical Journal 2024)
Iran South Med J 2024, 26(5): 324-340 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sobhani F, Arad B, Mahyar A, Barikani A. The Rate of Relapse of Primary Monosymptomatic Nocturnal Enuresis with Desmopressin Treatment in Comparison with Combined Treatment of Desmopressin and Tolterodine in Children Aged 5 to 16 Years. Iran South Med J 2024; 26 (5) :324-340
URL: http://ismj.bpums.ac.ir/article-1-1887-en.html
URL: http://ismj.bpums.ac.ir/article-1-1887-en.html
1- Children Growth Research Center, Research Institute for Prevention of Non- Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
2- Children Growth Research Center, Research Institute for Prevention of Non- Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran ,banafsheh.arad@gmail.com
2- Children Growth Research Center, Research Institute for Prevention of Non- Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran ,
Abstract: (548 Views)
Background: In the process of treating children with primary monosymptomatic nocturnal enuresis (PMNE), the relapse of PMNE after stopping the medicine causes the child to take the medicine for a prolonged time. The purpose of this study is to compare the rate of disease relapse in two groups of PMNE treatment with a combination of desmopressin + tolterodine and desmopressin alone.
Materials and Methods: One hundred twenty-three patients of both genders, suffering from nocturnal enuresis, 5-16 years old, were examined in a randomized, single-blind, single-center clinical trial. The first group was given one puff of desmopressin nasal spray and the second group was given one puff of desmopressin nasal spray + 1 mg tolterodine one hour before going to sleep. Data were analyzed using SPSS 21 software and Chi-Square and student t-test (P<0.05).
Results: The positive response of the patients to the treatment in the desmopressin treatment group was 100% and the relapse rate after stopping the treatment was 47.1%. In the desmopressin + tolterodine group, 96.4% responded positively to the treatment, and relapse after stopping the treatment was observed in 34.5% of them. There was no significant difference between the two groups in terms of response rate to treatment (P=0.11) and relapse after stopping the treatment (P=0.16).
Conclusion: Treatment with desmopressin and desmopressin + tolterodine was effective in reducing PMNE relapse after the initial treatment process in children. Considering that there was no statistically significant difference between the desmopressin and desmopressin + tolterodine treatment groups, there is no need to add tolterodine to the treatment regimen of nocturnal enuresis.
Materials and Methods: One hundred twenty-three patients of both genders, suffering from nocturnal enuresis, 5-16 years old, were examined in a randomized, single-blind, single-center clinical trial. The first group was given one puff of desmopressin nasal spray and the second group was given one puff of desmopressin nasal spray + 1 mg tolterodine one hour before going to sleep. Data were analyzed using SPSS 21 software and Chi-Square and student t-test (P<0.05).
Results: The positive response of the patients to the treatment in the desmopressin treatment group was 100% and the relapse rate after stopping the treatment was 47.1%. In the desmopressin + tolterodine group, 96.4% responded positively to the treatment, and relapse after stopping the treatment was observed in 34.5% of them. There was no significant difference between the two groups in terms of response rate to treatment (P=0.11) and relapse after stopping the treatment (P=0.16).
Conclusion: Treatment with desmopressin and desmopressin + tolterodine was effective in reducing PMNE relapse after the initial treatment process in children. Considering that there was no statistically significant difference between the desmopressin and desmopressin + tolterodine treatment groups, there is no need to add tolterodine to the treatment regimen of nocturnal enuresis.
Keywords: Nocturnal enuresis relapse, desmopressin, tolterodine, primary monosymptomatic nocturnal enuresis
Type of Study: Original |
Subject:
General
Received: 2023/09/17 | Accepted: 2024/04/9 | Published: 2024/05/5
Received: 2023/09/17 | Accepted: 2024/04/9 | Published: 2024/05/5
References
1. Sarabi M, Nikpasand N, Mahmoudabadi E, et al. Comprehensive Review of Nocturnal Enuresis in Chil-dren. J Pediatr Rev 2022; 10(3): 227-38. [DOI]
2. Cakiroglu B, Tas T, Eyyupoglu SE, et al. The adverse influence of spina bifida occulta on the medical treatment outcome of primary monosymptomatic nocturnal enuresis. Arch Ital Urol Androl 2014; 86(4): 270-3. [DOI]
3. Azarfar A, Esmaeili M, Naseri M, et al. Comparison of combined treatment with desmopressin plus oxybutynin and desmopressin plus tolterodine in treatment of children with primary nocturnal enuresis. J Renal Inj Prev 2015; 4(3): 80-6. [DOI]
4. Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the international children's continence society. Neurourol Urodyn 2016; 35(4): 471-81. [DOI]
5. Lee GK, Chung JM, Lee SD. First-morning urine osmolality and nocturnal enuresis in children: A single-center prospective cohort study. Investig Clin Urol 2023; 64(5): 501-9. [DOI]
6. Keten T, Aslan Y, Balci M, et al. Comparison of the efficacy of desmopressin fast-melting formulation and enuretic alarm in the treatment of monosymptomatic nocturnal enuresis. J Pediatr Urol 2020; 16(5): 645.e1-645.e7. [DOI]
7. Mohammadpour A, Basiri Moghaddam M, Jani S, et al. Survey of enuresis frequency and its associated factors among school children. Intern Med Today 2012; 18(2): 37-44. [Article]
8. Neveus T, Eggert P, Evans J, et al. Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children's Continence Society. J Urol 2010; 183(2): 441-7. [DOI]
9. Vande Walle J, Stockner M, Raes A, et al. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2007; 2(3): 232-8. [DOI]
10. Nevéus T, Fonseca E, Franco I, et al. Management and treatment of nocturnal enuresis-an updated standardization document from the International Children's Continence Society. J Pediatr Urol 2020; 16(1): 10-19. [DOI]
11. Ghanavati PM, Khazaeli D, Amjadzadeh M. A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial. Int Braz J Urol 2021; 47(1): 73-81. [DOI]
12. Alloussi SH, Mürtz G, Gitzhofer S, et al. Failure of monotherapy in primary monosymptomatic enuresis: a combined desmopressin and propiverine treatment regimen improves efficacy outcomes. BJU Int 2009; 103(12): 1706-12. [DOI]
13. Marzuillo P, Marotta R, Guarino S, et al. 'Frequently recurring' nocturnal polyuria is predictive of response to desmopressin in monosymptomatic nocturnal enuresis in childhood. J Pediatr Urol 2019; 15(2): 166.e1-166.e7. [DOI]
14. Radvanska E, Kovács L, Rittig S. The role of bladder capacity in antidiuretic and anticholinergic treatment for nocturnal enuresis. J Urol 2006; 176(2): 764-8. [DOI]
15. Montaldo P, Tafuro L, Rea M, et al. Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double‐blind, placebo‐controlled trial and an as-sessment of predictive factors. BJU Int 2012; 110(8 Pt B): E381-6. [DOI]
16. Shim M, Bang WJ, Oh CY, et al. Effect of desmopressin lyophilisate (MELT) plus anticholinergics combination on functional bladder capacity and therapeutic outcome as the first-line treatment for primary monosymptomatic nocturnal enuresis: A randomized clinical trial. Investig Clin Urol 2021; 62(3): 331-9. [DOI]
17. Kazi A, Moorani KN, Zehra S, et al. Comparative response of desmopressin versus combination therapy (desmopressin+oxybutynin) in children with nocturnal enuresis. Pak J Med Sci 2020; 36(6): 1263-9. [DOI]
18. Sharifiaghdas F, Sharifiaghdas S, Taheri M. Primary monosymptomatic nocturnal enuresis: monotherapy vs combination therapy. Urology 2016; 93: 170-4. [DOI]
19. Park SJ, Park JM, Pai KS, et al. Desmopressin alone versus desmopressin and an anticholinergic in the first-line treatment of primary monosymptomatic nocturnal enuresis: a multicenter study. Pediatr Nephrol 2014; 29(7): 1195-200. [DOI]
20. Austin PF, Ferguson G, Yan Y, et al. Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial. Pediatrics 2008; 122(5): 1027-32. [DOI]
21. Kazemi Rashed F, Nourizade D, Hajebrahimi S, et al. Does combination therapy with desmopressin and tolterodine improve the treatment outcomes of patients with monosymptomatic nocturnal enuresis? A randomized clinical controlled trial. ISRN Urol 2013; 2013: 413146. [DOI]
22. Bastos JM Netto, Rondon AV, de Lima GRM, et al. Brazilian consensus in enuresisrecomendations for clinical practice. Int Braz J Urol 2019; 45(5): 889-900. [DOI]
23. Alloussi SH, Mürtz G, Lang C, et al. Desmopressin treatment regimens in monosymptomatic and nonmonosymptomatic enuresis: A review from a clinical perspective. J Pediatr Urol 2011; 7(1): 10-20. [DOI]
24. Zaffanello M, Giacomello L, Brugnara M, et al. Therapeutic options in childhood nocturnal enuresis. Minerva Urol Nefrol 2007; 59(2): 199-205. [PubMed]
25. Madersbacher H, MuÈrtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (nonneurogenic and neurogenic). World J Urol 2001; 19(5): 324-35. [DOI]
26. Chang SJ, Yang SS. Do uroflowmetry and post-void residual urine tests necessary in children with primary nocturnal enuresis? Int Braz J Urol 2018; 44(4): 805-11. [DOI]
27. Pouladfar G, Monfared M, Abedini G. The prevalence of recurrent abdominal pain and some relative factors among children beginning primary school in Bushehr port. Iran South Med J 2005; 7(2): 162-72. [Article]
28. Gharepapagh E, Aryanpour F, Fakhari A, et al. Prevalence and intensity of vesicoureteral reflux in children with UTI based on direct radionuclide cystography. Iran South Med J 2024; 26(4): 248-59. [Article]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
